Back to top

Cantor Fitzgerald Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Cantor Fitzgerald analyst Li Watsek maintained a Buy rating on Ascendis Pharma yesterday and set a price target of $300.00. Watsek covers the Healt...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ascendis Pharma A/S (ASND)